Skip to contentG
GT Biopharma, Inc.
G
GTBPGT Biopharma, Inc. Q1 2019 · 10-Q
Revenue$0.00$0.00— vs Q1 2018 Net Income-$4.51M-$4.51MN/M vs Q1 2018 EPS Diluted-$0.09-$0.09N/M vs Q1 2018 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
GT Biopharma, Inc. · CIK 109657 · Engraved from SEC EDGAR
-$4,056,000
N/M
Operating Cash Flow-$961,000N/M Free Cash Flowderived-$961,000N/M ended Mar 31, 2019 · filed May 15, 2019 · 45 d after period end